Project Grant R01MH136990
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $900,000 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to Children's Hospital Medical Center in Cincinnati, Ohio. This 5-year grant, with a start date of September 18, 2025 and an end date of August 31, 2030, will fund mechanistic and translational research on brain neurophysiology and phenotypic heterogeneity in Fragile X Syndrome (FXS). The research...
- This federal Project Grant award of $670,675, granted by the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242), aims to advance the understanding of the clinical phenotypes and underlying mechanisms associated with Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS) and Fragile X-Associated Neuropsychiatric Disorders (FXAND) across the lifespan. The award will support two research projects: Project 1 will identify the developmental...
- This Project Grant award of $425,628.00 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research federal grant program (CFDA 93.865), aims to elucidate the role of the FMR1 gene in regulating reproductive function. The overarching goal is to investigate the molecular mechanisms by which FMR1 gene mutations, which cause Fragile X syndrome and premature ovarian failure, impact ovarian function...
- This federal Project Grant award of $430,375.00 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research on membrane trafficking impairments in Fragile X Syndrome. The research aims to investigate the underlying mechanisms by which the loss of the FMRP protein in Fragile X Syndrome leads to dysregulated surface expression of membrane proteins, which is believed...
- The Washington University Office of Sponsored Research Services Division received a $427,625 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865). The grant supports research to unravel the role of satellite glial cells in sensory hypersensitivity in Fragile X Syndrome, a leading genetic cause of autism spectrum disorders. Key activities include: Examining how...
- This $836,125.47 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants program (CFDA 93.242) aims to understand the molecular mechanisms governing lymphatic dysfunction in a mouse model of neurodevelopmental disorder, specifically Fragile X Syndrome (FXS). The research project will: 1) Determine how the FMR1 gene regulates meningeal lymphatic function, 2) Decipher the role of FMR1-induced lymphatic dysfunction in interferon gamma (IFNγ) T...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $515,898.00 to the Board of Regents of the University of Nebraska's University of Nebraska Medical Center (UNMC) division to conduct research on the contribution of astrocytes, a type of glial cell, to sleep/wake disturbances in Fragile X Syndrome (FXS). The key...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $187,500.00 to the University of South Florida to explore the role of the signaling protein Reelin in Fragile X Syndrome (FXS). The research aims to validate the use of a gene therapy approach to restore cognitive deficits in an FXS mouse model, as well as determine the mechanism...
- This $1,615,502 federal Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports a comprehensive research initiative focused on advancing scientific understanding of fragile X-associated conditions (FXACs). The five-year research project led by the Regents of the University of Michigan aims to achieve a deeper understanding of the genetic,...
- This $169,500 Project Grant award from the National Institute of Mental Health (NIMH) under the Mental Health Research Grants (CFDA 93.242) program supports research to identify the direct binding targets of the transcription factor FOXP1 in human cortical neural progenitor cells and neurons. The goal is to further the understanding of the disease mechanisms underlying FOXP1 syndrome, a rare neurodevelopmental disorder causing severe language and other impairments. The research will use...
POSTNATAL TRANSIENT CONNECTIVITY IN BRAIN DEVELOPMENT AND IMPLICATIONS IN FRAGILE X SYNDROME - ABSTRACT FRAGILE X SYNDROME (FXS) IS THE MOST COMMON GENETIC CAUSE OF AUTISM SPECTRUM DISORDERS. AUTISM SYMPTOMS IN FXS PATIENTS TYPICALLY MANIFEST DURING EARLY INFANCY WHEN CHILDREN ACTIVELY INTERACT WITH THEIR ENVIRONMENT AND FORM SENSORY-COGNITIVE ASSOCIATIONS. DURING THIS STAGE, THE NEOCORTEX UNDERGOES EXTENSIVE EXPERIENCE-DEPENDENT SYNAPTOGENESIS AND SYNAPTIC PRUNING TO EITHER MAINTAIN OR ELIMINATE, SO-CALLED TRANSIENT, NEURONAL CIRCUITS. SEVERAL STUDIES SUGGEST THAT BOTH SENSORY AND NEUROMODULATORY INPUTS TO THE CORTEX CAN ESTABLISH TRANSIENT CONNECTIONS WITH SPECIFIC CELL-TYPES, AND SUBSEQUENTLY CONTRIBUTE TO THE MATURATION OF PROPER ADULT CORTICAL CIRCUITS. GIVEN THAT EARLY BEHAVIORAL THERAPY IS WIDELY CONSIDERED TO BE THE MOST EFFECTIVE TREATMENT FOR CHILDREN WITH AUTISM, PHARMACOLOGICAL MANIPULATIONS OF SENSORY AND NEUROMODULATORY TRANSIENT CONNECTIVITY AT THE EARLY ONSET OF THE DISORDERS COULD POTENTIALLY MIMIC OR SYNERGIZE WITH THE EFFECTS OF SUCH BENEFICIAL BEHAVIORAL THERAPIES. HOWEVER, TO DATE, THE ROLE AND MECHANISMS OF TRANSIENT CONNECTIVITY IN NORMAL AND FXS- ASSOCIATED CORTICAL MATURATION REMAIN LARGELY UNKNOWN. TO ADDRESS THIS KNOWLEDGE GAP, WE PROPOSE TO INVESTIGATE THE MECHANISMS OF TRANSIENT CONNECTIVITY UNDERLYING SENSORY- AND NEUROMODULATORY-DEPENDENT CORTICAL MATURATION IN CONTROL MICE AND IN A MOUSE MODEL OF FXS. SENSORY EXPERIENCES ARE ENCODED IN THE CORTEX BY THALAMOCORTICAL (TC) NEURONS FORMING TRANSIENT CONNECTIONS WITH A SUBSET OF INHIBITORY NEURONS, THE SOMATOSTATIN (SST) CELLS. THESE TRANSIENT CONNECTIONS ARE BELIEVED TO CONTROL MATURATION OF EXCITATION/INHIBITION (E/I) BALANCE IN THE CORTEX, WHICH IS ALTERED IN THE MATURE BRAIN OF FXS MICE OR PATIENTS. OUR MOUSE DATA INDICATE THAT, IN PARALLEL TO SENSORY TC INPUTS, SST NEURONS RECEIVE CHOLINERGIC MODULATORY INPUTS ASSOCIATED WITH THE EARLY DEVELOPMENT OF TC PATHWAYS. THEREFORE, WE HYPOTHESIZE THAT THE SYNERGY BETWEEN TC AND CHOLINERGIC TRANSIENT CONNECTIVITY TO SST NEURONS IS AN INSTRUCTIVE MECHANISM THAT TRIGGERS CORTICAL MATURATION AND THAT THIS MECHANISM IS IMPAIRED IN FXS. OUR PREVIOUS RESEARCH USING COMBINATORIAL MOUSE GENETICS AND VIRAL CHEMOGENETIC APPROACHES SHOWED THAT METABOTROPIC SIGNALING CONTROLS THE FORMATION OF TRANSIENT TC INPUTS TO SST NEURONS. BASED ON THIS DATA, WE PROPOSE THAT CORTICAL E/I MATURATION RESULTS FROM METABOTROPIC SIGNALING THAT TRANSIENTLY TRANSDUCES SENSORY CUES AND NEUROMODULATION ONTO SST NEURONS. TO TEST THIS HYPOTHESIS, WE WILL EMPLOY MULTIDISCIPLINARY APPROACHES TO INVESTIGATE WHETHER TRANSIENT TC CONNECTIVITY GOVERNS HEALTHY AND FXS CORTICAL MATURATION (AIM 1), ELUCIDATE THE ROLE OF CHOLINERGIC INPUTS IN THE MATURATION OF HEALTHY AND FXS CORTICAL CIRCUITS (AIM 2), AND CHARACTERIZE METABOTROPIC MOLECULAR PATHWAYS UNDERLYING TRANSIENT CONNECTIVITY (AIM 3). OVERALL, OUR WORK WILL PROVIDE NOVEL INSIGHTS INTO THE ROLE OF TRANSIENT CONNECTIVITY ON SENSORY AND COGNITIVE EXPERIENCE-DEPENDENT CORTICAL MATURATION AND LAY THE FOUNDATIONS FOR EXPLORING APPROACHES TARGETING THE ONSET OF CIRCUIT DYSFUNCTIONS IN FXS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $117.8k | 9/23/25 | ||
| Not listed | $667.3k | 1/23/25 | ||
| Not listed | $667.3k | 1/23/25 | ||
| Not listed | $691.0k | 6/27/24 | ||
| Not listed | $691.0k | 6/27/24 |